Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer...
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of...
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically...
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014...
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the...
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at...
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug...
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12,...
LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today presented data from...
NAPERVILLE, Ill., Sept. 13, 2024 /PRNewswire/ -- Cloudbyz, a leader in cloud-based clinical trial management solutions, is proud to be...
New Platform Analyzes Millions of Data Points from Nutrition Products, Ingredients and Clinical Science to Provide Competitive Insights in Real...
Before the start of the ESMO congress, MEDSIR has brought together scientists, researchers, pharmaceutical companies, and patient association representatives to...
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune...
SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB...
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues...
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing...
Kevin Riley, industry leader with global experience in technology commercialization, joins as presidentCarolyn Magill steps down as CEO; Jeremy Rassen,...
As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the...
FREMONT, Calif., Sept. 12, 2024 /PRNewswire/ -- The 34th Medical Informatics Europe Conference was held in Athens, Greece August 25-29, 2024....